Bicara Therapeutics Inc. (BCAX)
NASDAQ:BCAX
Want to see BCAX full AI Analyst Report?
BCAX Stock Chart & Stats
$24.01
-$0.31(-1.97%)
At close: 4:00 PM EST
$24.01
-$0.31(-1.97%)
Day’s Range― - ―
52-Week Range$8.48 - $24.25
Previous CloseN/A
Volume80.52K
Average Volume (3M)526.79K
Market Cap
$1.43B
Enterprise Value$869.43M
Total Cash (Recent Filing)$539.75M
Total Debt (Recent Filing)$1.44M
Price to Earnings (P/E)―
Beta1.53
Next Earnings
Aug 18, 2026EPS Estimate
-0.82Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.78
Shares Outstanding65,703,865
10 Day Avg. Volume536,254
30 Day Avg. Volume526,791
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)2.29
Price to Sales (P/S)0.00
P/FCF Ratio-8.59
Enterprise Value/Market Cap0.61
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-5.54
Forecast
1Y Price Target
$32.11Price Target Upside33.74% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-3.41
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet & RunwayA large cash balance and explicit runway into H1 2029 materially reduce near-term financing pressure, allowing Bicara to complete pivotal FORTIFI‑HN01 enrollment, initiate the alternative dosing study and fund prelaunch investments without immediate dilution, improving execution optionality.
Compelling Clinical Efficacy SignalsDurable responses and multi-year survival signals across cohorts support a differentiated efficacy profile and the TGF‑β inhibition hypothesis, increasing probability of regulatory success and commercial adoption in first‑line HPV‑negative HNSCC versus existing SOC over the medium term.
Commercial Build-out & Addressable MarketHiring a CCO and building market access ahead of potential approval signal organizational readiness to commercialize. Combined with a large >$5B head‑and‑neck market and a clear initial patient segment, this strengthens the company's ability to capture commercial upside if clinical/regulatory milestones are met.
Bears Say
Pre-revenue With Widening LossesRemaining pre-revenue with materially larger TTM losses means the firm must rely on capital markets, partnerships or milestone payments to progress. Sustained negative earnings reduce flexibility and increase dilution or reprioritization risk if pivotal or ASCO readouts disappoint.
Weak Cash Generation / Rising Cash BurnOperating and free cash flow are consistently negative and tracking close to net losses, meaning reported losses convert into real cash outflows. Even with current runway, continued high burn raises the probability of future financings or partnerships before commercial revenue materializes.
Rising Operating & Commercialization ExpensesAs Bicara shifts toward commercial readiness, SG&A, manufacturing and development costs are set to rise. This structurally increases burn and could compress runway or force tradeoffs between indications or programs, making execution and cash planning more critical over the next 2–6 months.
Bicara Therapeutics Inc. News
BCAX FAQ
What was Bicara Therapeutics Inc.’s price range in the past 12 months?
Bicara Therapeutics Inc. lowest stock price was $8.48 and its highest was $24.25 in the past 12 months.
What is Bicara Therapeutics Inc.’s market cap?
Bicara Therapeutics Inc.’s market cap is $1.43B.
When is Bicara Therapeutics Inc.’s upcoming earnings report date?
Bicara Therapeutics Inc.’s upcoming earnings report date is Aug 18, 2026 which is in 64 days.
How were Bicara Therapeutics Inc.’s earnings last quarter?
Bicara Therapeutics Inc. released its earnings results on May 11, 2026. The company reported -$0.93 earnings per share for the quarter, missing the consensus estimate of -$0.649 by -$0.281.
Is Bicara Therapeutics Inc. overvalued?
According to Wall Street analysts Bicara Therapeutics Inc.’s price is currently Undervalued.
Does Bicara Therapeutics Inc. pay dividends?
Bicara Therapeutics Inc. does not currently pay dividends.
What is Bicara Therapeutics Inc.’s EPS estimate?
Bicara Therapeutics Inc.’s EPS estimate is -0.82.
How many shares outstanding does Bicara Therapeutics Inc. have?
Bicara Therapeutics Inc. has 65,703,865 shares outstanding.
What happened to Bicara Therapeutics Inc.’s price movement after its last earnings report?
Bicara Therapeutics Inc. reported an EPS of -$0.93 in its last earnings report, missing expectations of -$0.649. Following the earnings report the stock price went up 1.506%.
Which hedge fund is a major shareholder of Bicara Therapeutics Inc.?
Currently, no hedge funds are holding shares in BCAX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bicara Therapeutics Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$32.11 (33.74% Upside)
$32.11 (33.74% Upside)
Blogger Sentiment
Bullish
BCAX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 474.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 12.1%
Last 30 Days ▲ 12.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
87.46%
12-Months-Change
Fundamentals
Return on Equity
-35.89%
Trailing 12-Months
Asset Growth
15.80%
Trailing 12-Months
Company Description
Bicara Therapeutics Inc.
Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors. At the forefront of their pipeline is ficerafusp alfa, a unique antibody designed to tackle solid cancers. This bifunctional therapeutic agent works by simultaneously engaging the epidermal growth factor receptor (EGFR) and binding to human transforming growth factor beta (TGF-b). Bicara Therapeutics operates as a subsidiary of Biocon Limited.
BCAX Company Deck
BCAX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong positive clinical momentum for ficera (deep, durable responses, peer-reviewed publication, planned pivotal interim in mid-2027 and upcoming 3‑year ASCO data), meaningful commercial and organizational build-out, and a bolstered balance sheet providing runway into H1 2029. Offsetting risks include rising operating expenses, limited size/maturity of some cohorts, regulatory/design considerations for the alternative dosing study, and competitive/expansion challenges in tough indications like CRC. On balance, the highlights — notably compelling clinical efficacy signals and secured funding — substantially outweigh the lowlights, but key open milestones (ASCO updates, interim analysis, alternative dosing readout) remain important near‑term catalysts and risks.View all BCAX earnings summariesBCAX Stock 12 Month Forecast
Average Price Target
$32.11
▲(33.74% Upside)
Technical Analysis
Arbutus Biopharma
―
Bicycle Therapeutics
―
Relay Therapeutics
―
Zenas BioPharma, Inc.
―
Upstream Bio, Inc.
―
Ownership Overview
21.76% Insiders
13.32% Mutual Funds
24.51% Other Institutional Investors
32.70% Public Companies and
Individual Investors